Enanta Pharmaceuticals (ENTA) presents a negative equity recovery posture under a liquidation lens, consistent with the MFFAIS-computed cash liquidation value of approximately negative $118M and liquid liquidation value of approximately negative $110M as of March 31, 2026. The company holds $227.0M in cash, cash equivalents, and short- and long-term marketable securities at period end, down from $241.9M at December 31, 2025, reflecting six months of net operating cash burn of $18.9M and net investment in marketable securities. Under a liquidation scenario, these liquid assets recover at or near face value (cash/equivalents 100%, marketable securities near par for investment-grade instruments), making this the dominant asset class for recovery purposes. All other assets — PP&E, right-of-use assets, and any intangibles — would recover at significant haircuts or zero, consistent with a pre-revenue clinical-stage pharmaceutical company. The principal liability driving negative recovery is the OMERS royalty sale liability. In April 2023, ENTA received $200.0M in exchange for 54.5% of future MAVYRET/MAVIRET quarterly royalties through June 30, 2032, subject to a 1.42x aggregate cap ($284.0M). This obligation is carried on the balance sheet as a liability reduced by payments made to OMERS over the term. The filing does not separately disclose the current carrying balance of this liability in the XBRL tags provided, but it is discussed in MD&A and has been declining as royalty payments flow through. At face value in liquidation, the remaining obligation to OMERS plus ongoing lease commitments — total minimum lease payments aggregate approximately $81.8M ($4.2M remainder of FY2026, $8.7M in 2027, $9.0M in 2028, $9.3M in 2029, $9.5M in 2030, $41.1M thereafter) — substantially offset liquid asset recovery. Additionally, 1.9M shares of Series 1 nonconvertible preferred stock classified as a long-term liability at fair value of $1.3M carries a $2.0M liquidation preference payable upon qualifying merger or sale, adding a modest but face-value senior claim. The OMERS royalty sale liability is the dominant negative driver: even if the remaining balance has declined meaningfully from the original $200M as royalty payments have been remitted since Q3 FY2023, the combination of that liability, lease obligations, accrued liabilities, and preferred stock liquidation preference exceeds recoverable liquid assets at a total balance sheet level. No goodwill, in-process R&D, or other intangibles are noted as significant balance sheet items; all pipeline programs (zelicapavir/RSV, EDP-978/immunology, KIT, STAT6, MRGPRX2) are expensed as incurred, so intangible asset haircut is not a meaningful factor. Quarter-over-quarter, liquid assets declined by approximately $14.9M from December 31, 2025 to March 31, 2026, consistent with operating burn partially offset by retention of 45.5% of HCV royalties. The royalty sale agreement's OMERS liability and the lease stack are disclosed in MD&A but no XBRL tags were emitted for the specific balances of these liabilities in the TAG_CONTEXT provided, precluding tag-level analysis. The filing does not separately tag the OMERS liability balance, operating lease liability, or marketable securities breakdown in XBRL in this submission.
▼ Community Notes